What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing ...

The S&P500 (SP500)closed in the red, after the week witnessed muted inflation data, a court striking down President Trump's ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals (NASDAQ:REGN), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Investing.com -- Shares in Sanofi (EPA: SASY) (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) fell Friday after the pharmaceutical ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Intellia Therapeutics (NASDAQ:NTLA) shares tumbled in the premarket on Thursday after the biotech disclosed that a patient ...